Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT324 vs Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Phase 3Recruiting
- Sponsor
- BioNTech SE
- Start
- Apr 2026
- Primary completion
- Feb 2031
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of db-1311 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by BioNTech SE. Started Apr 2026; status: recruiting.
02
Drugs
db-1311
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07365995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365995.